JP2010502600A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502600A5
JP2010502600A5 JP2009526572A JP2009526572A JP2010502600A5 JP 2010502600 A5 JP2010502600 A5 JP 2010502600A5 JP 2009526572 A JP2009526572 A JP 2009526572A JP 2009526572 A JP2009526572 A JP 2009526572A JP 2010502600 A5 JP2010502600 A5 JP 2010502600A5
Authority
JP
Japan
Prior art keywords
plasminogen
use according
infectious disease
compound
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009526572A
Other languages
English (en)
Japanese (ja)
Other versions
JP5566105B2 (ja
JP2010502600A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2007/050585 external-priority patent/WO2008026999A2/en
Publication of JP2010502600A publication Critical patent/JP2010502600A/ja
Publication of JP2010502600A5 publication Critical patent/JP2010502600A5/ja
Application granted granted Critical
Publication of JP5566105B2 publication Critical patent/JP5566105B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009526572A 2006-08-28 2007-08-28 感染症に対する候補薬 Expired - Fee Related JP5566105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82366506P 2006-08-28 2006-08-28
US60/823,665 2006-08-28
PCT/SE2007/050585 WO2008026999A2 (en) 2006-08-28 2007-08-28 Candidates against infection

Publications (3)

Publication Number Publication Date
JP2010502600A JP2010502600A (ja) 2010-01-28
JP2010502600A5 true JP2010502600A5 (cg-RX-API-DMAC7.html) 2010-09-09
JP5566105B2 JP5566105B2 (ja) 2014-08-06

Family

ID=39136397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526572A Expired - Fee Related JP5566105B2 (ja) 2006-08-28 2007-08-28 感染症に対する候補薬

Country Status (12)

Country Link
US (3) US8318661B2 (cg-RX-API-DMAC7.html)
EP (1) EP2056864B1 (cg-RX-API-DMAC7.html)
JP (1) JP5566105B2 (cg-RX-API-DMAC7.html)
KR (1) KR101517626B1 (cg-RX-API-DMAC7.html)
CN (2) CN101573134B (cg-RX-API-DMAC7.html)
AU (1) AU2007290881B2 (cg-RX-API-DMAC7.html)
CA (1) CA2662101C (cg-RX-API-DMAC7.html)
DK (1) DK2056864T3 (cg-RX-API-DMAC7.html)
EA (1) EA016250B1 (cg-RX-API-DMAC7.html)
ES (1) ES2451015T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009002226A (cg-RX-API-DMAC7.html)
WO (1) WO2008026999A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
RU2421192C1 (ru) * 2010-03-09 2011-06-20 Винера Гумаровна Нафикова Способ лечения хронического бактериального конъюнктивита
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CN106890321A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
EP3395355B1 (en) * 2015-12-18 2026-03-04 Talengen International Limited Plasminogen for use in treating cervical erosion
EP3395354B1 (en) * 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
TWI677347B (zh) * 2015-12-18 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肝組織損傷及其相關病症的方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドTalengen International Limited 糖尿病網膜症を予防または治療するための方法
CA3008466C (en) * 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CN108210904A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗动脉粥样硬化及其并发症的药物及其用途
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
WO2018107689A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂质肾损伤的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN107496911A (zh) * 2017-10-20 2017-12-22 滕敏子 一种外科手术后用于防肿胀、抗感染的愈合剂
CN113164564A (zh) * 2018-11-19 2021-07-23 诺尔玛克Ip股份有限公司 用于治疗或预防心内膜炎的安克洛酶
CN114174528B (zh) * 2019-08-07 2025-02-21 学校法人东京齿科大学 判别方法、荧光测定装置和检查剂
CN111742887A (zh) * 2019-12-19 2020-10-09 广西医科大学第一附属医院 放疗后分泌性中耳炎树鼩模型的建立方法
EP4094776A4 (en) * 2020-02-11 2023-05-17 Talengen International Limited METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN115845036B (zh) * 2023-02-20 2023-05-09 滨州益洁口腔有限公司 用于口腔种植体牙龈组织的蛋白酶及制备方法
JP2026526789A (ja) * 2023-07-20 2026-08-10 カトリック ユニヴェルシテット ルーヴェン ブドウ球菌性膿瘍の治療

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023143A (en) * 1959-10-14 1962-02-27 American Cyanamid Co Process for preparing a veterinary composition
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5397578A (en) * 1994-03-29 1995-03-14 Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" Method of treatment of chronic purulent inflammations of ear in children
US6372473B1 (en) 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
AU5390699A (en) 1998-07-24 2000-02-14 Pharmacal Biotechnologies, Inc. Osseous tissue reconstruction system and method
WO2000051538A1 (en) 1999-03-01 2000-09-08 Uab Research Foundation Porous tissue scaffolding materials and uses thereof
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030206906A1 (en) 2001-11-26 2003-11-06 Genentech, Inc. Catheter composition and uses thereof
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
CN1420126A (zh) 2002-07-10 2003-05-28 牛勃 一种重组人纤溶酶原Kringle5突变体蛋白rhPK-5的制备方法
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Similar Documents

Publication Publication Date Title
JP2011528713A5 (cg-RX-API-DMAC7.html)
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
WO2005011657A3 (en) Piperazine derivatives and their use as therapeutic agents
EP2368900A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE509629T1 (de) Kombination von iap-inhibitoren und flt3- inhibitoren
JP2007501251A5 (cg-RX-API-DMAC7.html)
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
JP2016507532A5 (cg-RX-API-DMAC7.html)
RU2008150615A (ru) Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
JP2010539179A5 (cg-RX-API-DMAC7.html)
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
JP2009503024A5 (cg-RX-API-DMAC7.html)
RU2015132369A (ru) Комбинированная терапия для лечения нозокомиальной пневмонии
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
CN112788950A (zh) 用于治疗伤口的铋-硫醇组合物和方法
BRPI0413964B8 (pt) ácido derivado do ácido carboxílico quinolona, sua composição e agente antibacterial
FR2850023B1 (fr) Medicaments pour le systeme nerveux
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JP2014504636A5 (cg-RX-API-DMAC7.html)